NCT00096161View on ClinicalTrials.gov

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 28, 2015

Study Completion Date

August 31, 2015

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveGraft Versus Host DiseaseHodgkin LymphomaMyelodysplastic/Myeloproliferative NeoplasmNon-Hodgkin LymphomaPlasma Cell MyelomaWaldenstrom Macroglobulinemia
Interventions
DRUG

Cyclosporine

Given PO

DRUG

Mycophenolate Mofetil

Given PO

DRUG

Pentostatin

Given IV

BIOLOGICAL

Therapeutic Allogeneic Lymphocytes

Given IV

Trial Locations (5)

10126

University of Torino, Torino

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

84143

LDS Hospital, Salt Lake City

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00096161 - Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter